CEL-SCI Co. (NYSEAMERICAN:CVM) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 643,794 shares, a decrease of 15.3% from the January 12th total of 759,737 shares. Approximately 5.9% of the company’s stock are sold short. Based on an average daily volume of 272,421 shares, the days-to-cover ratio is currently 2.4 days.

Separately, Dawson James restated a “neutral” rating on shares of CEL-SCI in a research note on Monday, October 16th.

CEL-SCI (NYSEAMERICAN:CVM) opened at $1.77 on Monday. CEL-SCI has a 12 month low of $1.46 and a 12 month high of $3.92. The company has a market cap of $21.77, a price-to-earnings ratio of -1.09 and a beta of -1.49.

CEL-SCI (NYSEAMERICAN:CVM) last announced its quarterly earnings results on Friday, December 29th. The company reported ($0.58) EPS for the quarter.

TRADEMARK VIOLATION WARNING: “CEL-SCI Co. (CVM) Short Interest Update” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/12/cel-sci-co-cvm-short-interest-update-3.html.

About CEL-SCI

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.